Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis.

ABSTRACT:

Background

Tamoxifen was recommended by NICE in 2013 for chemoprevention of breast cancer, but a recent survey suggested only a quarter of GPs are aware of this. We set out to measure the uptake of tamoxifen, and the alternative raloxifene, in national prescribing data sets.

Methods

Tamoxifen and raloxifene data were extracted from England's monthly prescribing data sets, October 2010-October 2017. We used interrupted time series analysis to reveal national and local responses to guidelines. We investigated variation between practices by calculating percentiles for prescribing rates and ratios of change.

Results

We found an increase in monthly tamoxifen prescribing following release of the guidelines, with an increase in gradient (p = 0.001) but no step change (p = 0.

SUBMITTER: Curtis HJ 

PROVIDER: S-EPMC5943266 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature